UK markets closed

Vivoryon Therapeutics N.V. (0R3M.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
0.8630+0.1430 (+19.86%)
At close: 05:44PM BST
Currency in EUR

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.27
52-week change 3-95.90%
S&P500 52-week change 325.01%
52-week high 319.4000
52-week low 30.5000
50-day moving average 37.2982
200-day moving average 39.9349

Share statistics

Avg vol (3-month) 33.01k
Avg vol (10-day) 310.28k
Shares outstanding 58.21M
Implied shares outstanding 6N/A
Float 821.26M
% held by insiders 125.56%
% held by institutions 136.21%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)30 Jun 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-42.85%
Return on equity (ttm)-78.74%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -26.36M
Net income avi to common (ttm)-26.29M
Diluted EPS (ttm)-0.6330
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)38.58M
Total cash per share (mrq)1.49
Total debt (mrq)85k
Total debt/equity (mrq)0.21%
Current ratio (mrq)19.45
Book value per share (mrq)1.60

Cash flow statement

Operating cash flow (ttm)-31.84M
Levered free cash flow (ttm)-13.26M